2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy

You are currently not logged in to PHD

To view this content, please login to your account, or within the login, click 'Create an Account' for guest access.

Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Steve Ommen, MD, FACC from the Mayo Clinic and Carolyn Ho, MD, FAHA from Brigham and Women's Hospital discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. They highlight the introduction of Mavacamten, the first cardiac myosin inhibitor, as a significant change following its FDA approval for symptomatic obstructive HCM.
Recommended Videos
Overview and Risk Factors of Cerebral Venous Thrombosis
Diagnosis and Management of Cerebral Venous Thrombosis Key Takeaways
Management of Cerebral Venous Thrombosis
Disparities in Healthcare: Exploring Supraventricular Tachycardia in Pregn...
Approach to Patient Decision Making for Cardiogenic Shock in Older Adults
saved video
Save Video

Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.

See Full Content
Video is not available. Please check the URL.